Industry Trends

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More




caBIG: Fostering Better Connections with Open Source Software



By Deborah Borfitz

January 5, 2009 | The free, open source clinical trials software tools of the cancer Biomedical Informatics Grid (caBIG) have been downloadable, in a single bundle, from the website of the National Cancer Institute (NCI) Center for Biomedical Informatics and Information Technology since early last year. With November’s release of the caBIG Clinical Trials Suite (version 1.1), individual components also have newfound speed and simplicity of use.

The Suite, overall, can be more easily configured and installed and has enhanced user interfaces and documentation, says John Speakman, associate director of clinical trials products and programs for the Center. While the software has been crafted in response to the needs of clinical researchers in oncology, it is “by and large generic” and thus widely applicable beyond cancer.

The idea is to “surround” electronic data capture (EDC) systems with management tools specific to sites and patients, says Speakman. It is also to demonstrate that disparate groups can “share data in a reliable, trustworthy way” across trials so as to spot important disease patterns. Use of the six-module caBIG Clinical Trials Suite is voluntary and no one is tracking its usage, but about 200 organizations (representing roughly 1,000 individuals) currently participate in the caBIG community.

The Suite includes a Clinical Participant Registry enabling clinical trials staff to track study subjects across multiple trials and sites. With the recent upgrade, the repository supports companion protocols, such as quality-of-life studies, which may be tied to a central therapeutic trial, says Speakman. Notification features have also been improved so that sites can set up rules for notification events.

The Suite’s Patient Study Calendar delineates “what happens when” for sites and patients and is able to adjust when the patient schedule changes, such as when an adverse event occurs. Sites can now use the module to self-style ad hoc reports on such topics as protocol compliance, says Speakman. They can also re-use study calendar templates, avoiding rework on complex trials. Sponsors, like the NCI, can likewise generate calendar templates on behalf of sites.

The Adverse Event (AE) Reporting System component is pre-programmed with the basic rules about NCI reporting, such as when an AE report must be expedited, says Speakman. But study investigators can also set up and edit their own AE-related rules. With the latest iteration of the module, they can also locally manage non-serious AEs in a more streamlined fashion. The system has a new “alert panel” whereby sites can monitor potential problems—as indicated by an out-of-range lab value, for instance—without opening up an AE report.

Study-defined solicited AEs, which sites are specifically required to ask patients about, are also now distinguishable from patient self-reported AEs, says Speakman. Sites can more easily import and export rule sets and information about subjects between instances of care as well as customized reports. The AE system also now enables coding of AEs using versions 10 and 11 of the Medical Dictionary for Regulatory Activities.

The Clinical Data Exchange application of the caBIG Clinical Trials Suite now integrates with open source databases and allows transfer of information other than lab data, says Speakman.

The other two modules of the Suite, which remain relatively unchanged, are the Clinical Trials Object Data System Lab Viewer—whereby lab data can be viewed and queried and subsets of tests can be sent to a clinical trials database—and a connector to the NCI’s EDC system (C3D), says Speakman. “Down the road, we hope to see a bunch of connectors for all the different EDC systems.”

As it is, organizations with in-house software engineers have been taking advantage of the software’s open source distribution to integrate the caBIG tools with their legacy EDC and clinical data management systems, says Speakman.


This story first appeared in eCliniqua, one of Bio-IT World’s free eNewsletters. Subscribe here.

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Life Science Webcasts & Podcasts

medidata podcast #8 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide  

Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:

  • Current practices in clinical trial logistics
  • Comparing advances in clinical supply practices to  other aspects of clinical trials 
  • Where current practices fall short of meeting the challenges
  • Trends and evolving improvements that may change the way logistics are conducted

Listen Now  


More Podcasts

Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 





Sponsored Links

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .